Publication | Closed Access

Ulinastatin is a novel candidate drug for sepsis and secondary acute lung injury, evidence from an optimized CLP rat model

InflammationAcute Lung InjuryNovel Candidate DrugMedicineSepsisPulmonary PharmacologyPharmacotherapyPharmacologyOxidative StressTissue Injury